Open AccessSurgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?
Author(s) -
Volker Steger,
T. Walker,
Migdat Mustafi,
K. Lehrach,
Thomas Kyriss,
Stefanie Veit,
Godehard Friedel,
Thorsten Walles
Publication year - 2012
Publication title -
interactive cardiovascular and thoracic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 56
eISSN - 1569-9293
pISSN - 1569-9285
DOI - 10.1093/icvts/ivs400
Subject(s) - medicine , mediastinal lymph node , stage (stratigraphy) , chemoradiotherapy , neoadjuvant therapy , surgery , lung cancer , lymph node , metastasis , retrospective cohort study , subgroup analysis , mediastinum , cancer , radiation therapy , oncology , confidence interval , breast cancer , biology , paleontology
Persistent mediastinal lymph node metastasis after neoadjuvant therapy is a significant negative indicator for survival. Even though there is still no consensus on the matter, some authors advocate a thorough restaging prior to surgery and deny surgery in cases of persistent N2 because of the poor outcome. We analysed our results after trimodal therapy in pN2/N3 stage III non-small-cell lung cancer (NSCLC) and persistent mediastinal lymph node metastasis after neoadjuvant chemoradiotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom